MA47719A - Esketamine pour le traitement de la dépression - Google Patents

Esketamine pour le traitement de la dépression

Info

Publication number
MA47719A
MA47719A MA047719A MA47719A MA47719A MA 47719 A MA47719 A MA 47719A MA 047719 A MA047719 A MA 047719A MA 47719 A MA47719 A MA 47719A MA 47719 A MA47719 A MA 47719A
Authority
MA
Morocco
Prior art keywords
esketamine
depression
treatment
Prior art date
Application number
MA047719A
Other languages
English (en)
Other versions
MA47719B1 (fr
Inventor
Carla Canuso
Ella Daly
Wayne Drevets
David Wood Hough
Adam Janik
Honglan Li
Rachel Ochs-Ross
Jaskaran Singh
Ewa Wajs
Peter Zannikos
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47719A publication Critical patent/MA47719A/fr
Publication of MA47719B1 publication Critical patent/MA47719B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA47719A 2017-12-22 2018-12-21 Esketamine pour le traitement de la dépression MA47719B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762609504P 2017-12-22 2017-12-22
US201862663206P 2018-04-26 2018-04-26
US201862663219P 2018-04-26 2018-04-26
US201862667406P 2018-05-04 2018-05-04
US201862675846P 2018-05-24 2018-05-24
US201862755905P 2018-11-05 2018-11-05
EP18215651.3A EP3501542B1 (fr) 2017-12-22 2018-12-21 Esketamine pour le traitement de la dépression

Publications (2)

Publication Number Publication Date
MA47719A true MA47719A (fr) 2020-01-15
MA47719B1 MA47719B1 (fr) 2026-03-31

Family

ID=65003585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47719A MA47719B1 (fr) 2017-12-22 2018-12-21 Esketamine pour le traitement de la dépression

Country Status (20)

Country Link
US (3) US11707440B2 (fr)
EP (1) EP3501542B1 (fr)
JP (3) JP7807870B2 (fr)
KR (1) KR20240011237A (fr)
CN (2) CN117531017A (fr)
AU (2) AU2018282466A1 (fr)
BR (1) BR112020012473A2 (fr)
CA (1) CA3086478A1 (fr)
DK (1) DK3501542T3 (fr)
FI (1) FI3501542T3 (fr)
IL (2) IL275482B1 (fr)
JO (1) JOP20200156A1 (fr)
MA (1) MA47719B1 (fr)
MX (2) MX2020006650A (fr)
PH (1) PH12020500555A1 (fr)
PT (1) PT3501542T (fr)
SG (1) SG11202005896WA (fr)
SM (1) SMT202600184T1 (fr)
TW (2) TWI843711B (fr)
WO (1) WO2019126108A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CA2961208A1 (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3863617A1 (fr) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Eskétamine pour une utilisation dans le traitement d'un trouble dépressif majeur
WO2020178653A1 (fr) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de la dépression
PT3976012T (pt) * 2019-05-31 2024-04-09 Afyx Therapeutics As Administração intranasal de cetamina a doentes com cefaleia em salvas
CA3133012A1 (fr) * 2019-08-05 2021-02-11 The Ketamine Research Foundation Ketamine pour le traitement de symptomes et de troubles post-partum
JP2022546456A (ja) 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20220339123A1 (en) * 2019-09-13 2022-10-27 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137148A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement de troubles neuropsychiatriques ou neurologiques
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
IL300547A (en) * 2020-08-18 2023-04-01 Oakwood Laboratories LLC Microsphere formulations comprising ketamine and methods for their production and use
CN116635941A (zh) * 2020-10-22 2023-08-22 通尼克斯医药控股公司 评估干预对疾病结果的重要性的随机化遵循方法
JP7847233B2 (ja) * 2022-04-26 2026-04-16 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド エスケタミン液体製剤及びその使用
WO2024201274A1 (fr) * 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Eskétamine destinée à être utilisée dans le traitement de la dépression
EP4732304A2 (fr) * 2023-06-21 2026-04-29 Cristcot LLC Développement et validation de mesure d'impact de symptômes d'une maladie hémorragique
WO2025106879A1 (fr) * 2023-11-15 2025-05-22 Gilgamesh Pharmaceuticals, Inc. Méthodes de traitement de troubles psychiatriques ou de la douleur à l'aide de (r)-2-(4-fluorophényl)-2-(méthylamino) cyclohexan-1-one ou de sels pharmaceutiquement acceptables de ceux-ci
WO2025160542A1 (fr) * 2024-01-26 2025-07-31 Inesket Llc Formulation de pulvérisation nasale de kétamine et méthodes d'utilisation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10025A (en) 1853-09-20 Improvement in turbines
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
CA2213567C (fr) 1995-02-24 2010-01-26 Stuart L. Weg Administration nasale et oculaire de ketamine pour soulager la douleur ou assurer une desintoxication
WO1997007750A1 (fr) 1995-08-30 1997-03-06 Weg Stuart L Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (fr) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
CA2423354C (fr) 2000-09-20 2009-12-15 Lee Shahinian Jr. Preparations et medications nasales, inhalables et ophtalmiques locales a conservation spontanee
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
EP1551393A4 (fr) 2002-07-30 2010-06-16 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (fr) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Utilisations analgesiques de norketamine et de promedicaments de ketamine/norketamine
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
WO2006130098A1 (fr) 2005-06-01 2006-12-07 Shl Medical Ab Administrateur de doses posologiques
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20070256688A1 (en) 2006-04-21 2007-11-08 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
CN104395283A (zh) 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2013138322A1 (fr) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014020155A1 (fr) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Formes d'administration transmuqueuse orale de kétamine s
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
WO2015031410A1 (fr) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Dose orale à couche unique de kétamine neuro-atténuante
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (fr) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Compositions et préparations combinées pour le traitement des douleurs oropharyngées
CA2936809A1 (fr) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprenant de la ketamine pour le traitement d'un trouble du spectre de l'autisme
EP3287124B1 (fr) 2014-04-17 2022-11-30 Ketabon GmbH Forme posologique orale de kétamine
ES2702330T3 (es) 2014-05-04 2019-02-28 Firmenich & Cie Alimentos y bebidas aromatizados
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
EP3179993B1 (fr) * 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine pour son utilisation dans une méthode de traitement de la dépression
CA2961208A1 (fr) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.

Also Published As

Publication number Publication date
SMT202600184T1 (it) 2026-05-12
JP2026027257A (ja) 2026-02-18
FI3501542T3 (fi) 2026-04-09
JP2024001204A (ja) 2024-01-09
JOP20200156A1 (ar) 2022-10-30
RU2020123893A3 (fr) 2022-04-29
PH12020500555A1 (en) 2021-05-17
NZ765616A (en) 2024-12-20
US11707440B2 (en) 2023-07-25
TW202415363A (zh) 2024-04-16
SG11202005896WA (en) 2020-07-29
DK3501542T3 (da) 2026-04-20
RU2020123893A (ru) 2022-01-24
KR20240011237A (ko) 2024-01-25
EP3501542B1 (fr) 2026-01-28
AU2024227438A1 (en) 2024-11-07
KR20200113197A (ko) 2020-10-06
CA3086478A1 (fr) 2019-06-27
CN117531017A (zh) 2024-02-09
JP7807870B2 (ja) 2026-01-28
MA47719B1 (fr) 2026-03-31
US20240000728A1 (en) 2024-01-04
JP2021506924A (ja) 2021-02-22
MX2023012450A (es) 2023-10-31
AU2018282466A1 (en) 2019-07-11
PT3501542T (pt) 2026-04-30
BR112020012473A2 (pt) 2020-11-24
US20250332121A1 (en) 2025-10-30
TWI843711B (zh) 2024-06-01
IL275482B1 (en) 2025-03-01
MX2020006650A (es) 2020-11-06
TW201940162A (zh) 2019-10-16
IL319020A (en) 2025-04-01
IL275482A (en) 2020-08-31
CN112423789A (zh) 2021-02-26
EP3501542A1 (fr) 2019-06-26
US20210386688A1 (en) 2021-12-16
WO2019126108A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA41449A (fr) Polythérapies pour le traitement de cancers
IL275482A (en) Asketamine for the treatment of depression
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3328374A4 (fr) Antagonistes de la glutamine pour le traitement de déficits cognitifs
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome